ClinicalTrials.Veeva

Menu

Evaluation of Performance, Safety and Benefit of the Wishbone HA as Bone Graft Substitute, a Pre-market Clinical Investigation

W

Wishbone SA

Status

Enrolling

Conditions

Safety Issues
Bone Regeneration

Treatments

Device: Tooth extraction and bone graft procedure

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06383377
Pre-market parallel study

Details and patient eligibility

About

This investigation is a pre-market, prospective, multi-center, randomized, single blinded, parallel controlled clinical investigation performed in at least 5 clinical centers for confirmatory purposes of the use of WHA as intended in the filling of extraction sockets to enhance preservation of the alveolar socket.

Full description

In this study, the subjects will be pseudonymized and randomized in a 1:1 ratio between WHA and the selected comparator device Bio-Oss®. The sample size of the study has been computed based on a non-inferiority test between Bio- Oss® and WHA for device performance for the filling of extraction sockets. A total of 96 subjects will be enrolled.

The results will be used to demonstrate the safety, performance and benefit of the product WHA in the socket indication in compliance with the MDR 2017/745.

The endpoints are all accurately based on objective measurements:

  • Primary Endpoint: Bone reconstruction as measured by CBCT (in mm) after bone grafting procedure.

  • Secondary Endpoints:

    • Evaluation of implant stability at placement.
    • Assessment of bone density at the time of implant insertion.
    • Implant osteointegration at 3months after implant placement.
    • Evaluation of implant survival and success at 3-, 6-and12-months, 3-and 5- years after implant placement.
    • Rate of all Adverse Device Events (incidence, type, relatedness, severity, seriousness) from the time of grafting procedure up to 5 years after implant placement.
    • Patient satisfaction 6- and 12-months after implant placement.
    • Evaluation of the Sulcus index (peri-implant marginal tissue health status) at 6- and 12-months after implant placement.

Enrollment

96 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • The subject signed the informed consent form;
  • The subject is ≥ 18 and ≤ 80 years old at surgery;
  • The subject is in need of a tooth extraction prior to implant placement;
  • All four bony walls are preserved after extraction;
  • Minimum 8mm height of bone;
  • Minimum 7mm thickness of lingual vestibular;
  • The subject is willing and able to comply with all investigation related procedures (such as exercising oral hygiene and attending all follow-up visits);
  • Full-mouth bleeding score (FMBS) lower than 25%;
  • Full-mouth plaque score (FMPI) lower than 25%.

Exclusion criteria

  • Subject with an acute infection (abscess) at the surgical site;
  • Subject with untreated periodontitis or periodontal disease;
  • Subject with autoimmune diseases or subjects that had received or were currently receiving treatment with antiresorptive drugs (e.g., bisphosphonates), or steroid therapy;
  • Subject who is pregnant or breastfeeding;
  • Subjects is a heavy smoker (>10 cigarettes a day);
  • Subject with an inability to conduct basic oral hygiene (poor oral hygiene and motivation);
  • Subject with metabolic diseases (diabetes, hyperparathyroidism, osteomalacia);
  • Subject with severe renal dysfunction and severe liver disease;
  • Subject with known severe osteoporosis;
  • Subject with multiple sclerosis and/or acromegaly;
  • Subject follows radiotherapy;
  • Subject with psychiatric disorders or under substance abuse (drug or alcohol);
  • Subject who participates in other clinical trials interfering with the present protocol;
  • Mucosal diseases in the areas to be treated.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

96 participants in 2 patient groups

Bio-Oss®
Active Comparator group
Description:
Tooth scheduled for extraction will be removed in the least traumatic way. The socket will be filled with the comparator (Bio-Oss® Geistlich, granules 0.25 - 1mm). Two follow up visits to monitor the healing process will take place at 2 and 6 weeks after surgery. Implant placement will be performed 4 months after the regenerative procedure. Implant loading will be allowed after having waited a minimum of 3 months after the implant placement and after a control visit. The implant survival and success will be assessed at 3, 6 and 12 months after implant placement. A long-term follow-up will evaluate the implant survival and success at 3 and 5 years post implant placement.
Treatment:
Device: Tooth extraction and bone graft procedure
WHA
Experimental group
Description:
Tooth scheduled for extraction will be removed in the least traumatic way. The socket will be filled with the investigational device (WHA, granules 0.25- 1.0mm). Two follow up visits to monitor the healing process will take place at 2 and 6 weeks after surgery. Implant placement will be performed 4 months after the regenerative procedure. Implant loading will be allowed after having waited a minimum of 3 months after the implant placement and after a control visit. The implant survival and success will be assessed at 3, 6 and 12 months after implant placement. A long-term follow-up will evaluate the implant survival and success at 3 and 5 years post implant placement.
Treatment:
Device: Tooth extraction and bone graft procedure

Trial contacts and locations

5

Loading...

Central trial contact

Emilie Dory, CEO; Justine Pirson, R&D Manager

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems